EMA — authorised 27 January 1999
- Application: EMEA/H/C/000223
- Marketing authorisation holder: Immedica Pharma AB
- Local brand name: Emadine
- Indication: Symptomatic treatment of seasonal allergic conjunctivitis.
- Status: approved
🇪🇺 Emadine in European Union
EMA authorised Emadine on 27 January 1999
Marketing authorisation
Emadine in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Immunology approved in European Union
Frequently asked questions
Is Emadine approved in European Union?
Yes. EMA authorised it on 27 January 1999.
Who is the marketing authorisation holder for Emadine in European Union?
Immedica Pharma AB holds the EU marketing authorisation.